Key Points

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported less-than-stellar earnings yesterday and announced it was ending the development of a significant portion of its pipeline. 10 stocks we like better than Recursion Pharmaceuticals ›

Shares of Recursion Pharmaceuticals(NASDAQ: RXRX) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly.

Recursion revealed disappointing first-quarter earnings on Monday and announced it would pare down its development pipeline. Recursion was also hit by a survey revealing that the biotech industry expects President Donald Trump's federal research cuts will make raising capital more challenging.

By the numbers

Recursion reported an earnings-per-share (EPS) loss of $0.50 on sales of $14.75 million. While the former ever so slightly beat Wall Street's expectations, the top-line figure was below the forecast of $14.98 million. The company also announced it was ending research on a significant portion of its pipeline in order to cut costs.

President Trump's cuts could make it harder for Recursion to stay afloat

The Trump administration has taken aim at the National Institutes of Health (NIH), which provides research dollars for biomedical research, as well as major research universities and other science organizations. A survey released Tuesday revealed that a majority of biotech leaders polled believed these cuts would make raising capital harder.Image source: Getty Images.

Recursion is still heavily investing in research and development and operates deep in the red. It will likely need outside funding to continue long-term and reach a point where its investments pay off.

Recursion has a long way to go

While Recursion's novel use of AI is promising and could lead to lucrative breakthroughs, there is a lot of uncertainty here. This is definitely a stock for aggressive, risk-tolerant investors. If that's you, Recursion could pay off, but it will take time, and there are no guarantees.

Should you invest $1,000 in Recursion Pharmaceuticals right now?

Before you buy stock in Recursion Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Story Continues

Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $617,181!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $719,371!*

Now, it’s worth notingStock Advisor’s total average return is909% — a market-crushing outperformance compared to163%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor.

See the 10 stocks »

*Stock Advisor returns as of May 5, 2025

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Why Recursion Pharmaceuticals Stock Plummeted 24% This Week was originally published by The Motley Fool

View Comments